In today’s briefing:
- CATL Chairman Sees Recycled Lithium as the Future of EV-Battery Making
- TCL Acquires LG Display’s LCD Plants in Guangzhou as Industry Consolidates
- China Healthcare Weekly (Oct.6) – WuXi to Sell Assets, Be Rational on China CXO, Sihuan Underperform
- Lalatech IPO | Review of H124 Financials & Operating Stats | Strike While the Iron Is Hot-Ish?
CATL Chairman Sees Recycled Lithium as the Future of EV-Battery Making
Half of all lithium-ion batteries could be made with recycled lithium by 2042, according to the founder of power cell giant Contemporary Amperex Technology Co. Ltd. (CATL) (300750.SZ +11.06%), who presented a vision of an eco-friendlier industry at a recent event.
Speaking at the World New Energy Vehicles Congress on Friday, Zeng Yuqun, also CATL’s chairman, highlighted the critical role power cells can play in driving the EV industry toward a zero-carbon future, saying that the sustainable development of the industry hinges on the use of recycled battery raw materials.
- CATL’s battery recycling business has already taken shape, with a current annual capacity to process 270,000 tons of used batteries, Zeng said.
TCL Acquires LG Display’s LCD Plants in Guangzhou as Industry Consolidates
- TCL Technology Group Corp.
- (000100.SZ +7.51%), a leading Chinese electronics maker, has agreed to pay 10.8 billion yuan ($1.54 billion) to acquire LG’s two display factories in Guangzhou, as Chinese manufacturers strengthen their dominance in the liquid crystal displays (LCD).
- TCL China Star Optoelectronics Technology (TCL CSOT), a subsidiary of TCL Technology, will acquire 80% of LG Display China and the entire stake of LG Display Guangzhou.
China Healthcare Weekly (Oct.6) – WuXi to Sell Assets, Be Rational on China CXO, Sihuan Underperform
- Investors always have expectations for Chinese CXOs, believing that BIOSECURE Act will not pass and Chinese CXOs will bottom out. We can understand this, but we have to be rational.
- Selling the operations that have been negatively affected is a reasonable choice, which helps stabilize WuXi’s business/market expectations. But this does not necessarily mean the geopolitical conflict will end here.
- Without persuasive long-term logic, share price of Sihuan would still underperform. Despite strong performance of Chinese stocks, we advise investors to do short-term trading on Sihuan Pharmaceutical Hldgs (460 HK).
Lalatech IPO | Review of H124 Financials & Operating Stats | Strike While the Iron Is Hot-Ish?
- In a new filing with HKEX, we can see Lalatech’s revenue growth slow
- The company’s grip on CoR loosened, but OpEx growth in H1 was minimal
- Given improving market conditions, we believe Lalatech may finally sell shares
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
